Ocular Hypertension News and Research

RSS

Ultra-processed foods linked to higher glaucoma risk, study warns

Study finds a significant relationship between the highest intake of ultra-processed foods, especially sweets, and an increased risk of developing glaucoma among Spanish university graduates, highlighting the importance of dietary quality for ocular health.

8 Apr 2024

Can genome editing transform ocular disease treatment?

The discovery and development of gene-editing technologies and their applications in managing ocular diseases.

3 Aug 2023

Intracranial pressure plays a key role in normal-tension glaucoma

An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 per cent of all glaucoma cases.

13 Feb 2023

The interplay of family history and genome-wide polygenic risk scores across 24 common diseases

A new study has investigated the interplay of FH and genome-wide PRS

11 Jul 2022

Mechanism behind how certain osmolytes cause kidney damage revealed

Researchers from Tokyo Metropolitan University have uncovered the mechanism by which osmolytes used to treat high fluid pressure in the eye and skull can cause kidney damage.

27 Feb 2022

Study finds that not all patients with elevated eye pressure need treatment to prevent vision loss

More than 20 years after the launch of a landmark clinical trial, follow-up examinations and analyses found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma.

16 Apr 2021

Smartphones could be used to reveal early-warning signs of glaucoma

Smartphones could be used to scan people's eyes for early-warning signs of glaucoma - helping to prevent severe ocular diseases and blindness, a new study reveals.

25 Feb 2021

Novel mechanism that may confer protection against glaucoma identified

A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.

17 Sep 2020

Tips on making a smooth transition to optimal eye care

If you have glaucoma, you're wondering: What will my new ophthalmologist need to hit the ground running and manage my disease? In my experience, to make a smooth transition to optimal care, the most important thing you can do is create a personal Glaucoma Data Portfolio.

13 Jul 2018

Trifocal lenses: the best chance of true spectacle independence?

Trifocal intraocular lenses (IOLs) represent the latest in premium lens technology. They are tiny, artificial lenses that are implanted into the eye during a cataract or lens replacement procedure.

28 Sep 2016

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

At the Israeli Society for Vision and Eye Research conference on March 10, the MedInsight Research Institute and Center for Drug Repurposing at Ariel University presented the latest findings on positive user-reported outcomes of the repurposed drug dipyridamole in treating pterygium and related dry-eye symptoms.

15 Mar 2016

New, regenerative medicine approach developed to remove congenital cataracts in infants

Researchers at University of California, San Diego School of Medicine and Shiley Eye Institute, with colleagues in China, have developed a new, regenerative medicine approach to remove congenital cataracts in infants, permitting remaining stem cells to regrow functional lenses.

10 Mar 2016

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.

1 Jul 2014

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA).

25 Jun 2014

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.

13 May 2014

Glial cells promise as new target to modulate retinal synaptic plasticity after retinal injury

Different types of retinal damage could induce plastic changes of retinal synapses, which might precede the serious damage of neuron soma.

7 May 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014